keyword
MENU ▼
Read by QxMD icon Read
search

cancer, malignant, oncology, hematology, chemotherapy

keyword
https://www.readbyqxmd.com/read/27634204/treatments-for-hematological-malignancies-in-contrast-to-those-for-solid-cancers-are-associated-with-reduced-red-cell-alloimmunization
#1
Dorothea Evers, Jaap Jan Zwaginga, Janneke Tijmensen, Rutger A Middelburg, Masja de Haas, Karen M K de Vooght, Daan van de Kerkhof, Otto Visser, Nathalie C V Péquériaux, Francisca Hudig, Johanna G van der Bom
Red cell alloimmunization may induce severe hemolytic side effects. Identification of risk modifying conditions will help tailor preventative strategies. This study aims to quantify the associations of hematological malignancies and solid cancers with red cell alloimmunization in patients receiving red cell transfusions. We performed a nested multicenter case-control study in a source population of 24,063 patients receiving their first and subsequent red cell transfusions during an eight year follow-up period...
September 15, 2016: Haematologica
https://www.readbyqxmd.com/read/27443290/how-i-treat-hepatitis-c-virus-infection-in-patients-with-hematologic-malignancies
#2
Harrys A Torres, George B McDonald
Hepatitis C virus (HCV) infection is not uncommon in cancer patients. Over the past 5 years, treatment of chronic HCV infection in patients with hematologic malignancies has evolved rapidly as safe and effective direct-acting antivirals (DAAs) have become the standard-of-care treatment. Today, chronic HCV infection should not prevent a patient from receiving cancer therapy or participating in clinical trials of chemotherapy because most infected patients can achieve virologic cure. Elimination of HCV from infected cancer patients confers virologic, hepatic, and oncologic advantages...
September 15, 2016: Blood
https://www.readbyqxmd.com/read/27400944/barriers-to-quality-end-of-life-care-for-patients-with-blood-cancers
#3
Oreofe O Odejide, Angel M Cronin, Nolan B Condron, Sean A Fletcher, Craig C Earle, James A Tulsky, Gregory A Abel
PURPOSE: Patients with blood cancers have been shown to receive suboptimal care at the end of life (EOL) when assessed with standard oncology quality measures (eg, no chemotherapy ≤ 14 days before death). As they were developed primarily for solid tumors, it is unclear if these measures are appropriate for patients with hematologic malignancies. Moreover, barriers to high-quality EOL care for this specific patient population are largely unknown. METHODS: In 2015, we asked a national cohort of hematologic oncologists about the acceptability of eight standard EOL quality measures...
September 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27320114/-incidence-and-risk-assessment-of-tumor-lysis-syndrome-in-patients-with-advanced-germ-cell-cancer
#4
Masahiro Kurobe, Koji Kawai, Ken Tanaka, Daishi Ichioka, Takayuki Yoshino, Shuya Kandori, Takashi Kawahara, Natsui Waku, Ei-Ichirou Takaoka, Takahiro Kojima, Akira Joraku, Takahiro Suetomi, Jun Miyazaki, Hiroyuki Nishiyama
Tumor lysis syndrome (TLS) is a major oncological emergency. TLS is common in patients with hematological malignancies, but it can occur across a spectrum of cancer types. Germ cell tumors (GCT) have rapid cancer cell turnover and often present with bulky metastasis. The international TLS expert consensus panel has recommended guidelines for a medical decision tree to assign low, intermediate and high risk to patients with cancer at risk for TLS. GCT is classified as intermediate risk for TLS, and the patients who have other TLS risks factors are classified to be at high risk for TLS...
May 2016: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/27296505/-application-of-immunomodulatory-therapeutic-antibodies-a-new-perspective-in-oncology
#5
Szilvia Szamosi, László Váróczy, Zoltán Szekanecz
In the past decade major advances in tumor immunology, a better understanding of antigen recognition by T-cells likewise discovering the regulatory inhibitory signals resulted in the development of new immunotherapies with promising durable responses in various solid tumor types and in hematologic malignancies. This review focuses on immunomodulatory antibodies, namely immune checkpoint inhibitor therapy. The prototype of this new class of immune stimulating agents was cytotoxic T-lymphocyte antigen-4 (CTLA-4) antagonists...
June 2016: Orvosi Hetilap
https://www.readbyqxmd.com/read/27206294/implementing-the-surviving-sepsis-campaign-in-an-ambulatory-clinic-for-patients-with-hematologic-malignancies
#6
Brenda K Shelton, Julie Stanik-Hutt, Joyce Kane, Richard J Jones
BACKGROUND: Infectious complications can occur in patients receiving cancer treatment and are the most common cause of death not directly related to malignancy. Established international best practices for recognition and management of early sepsis with bundled interventions reduce sepsis-related morbidity and mortality in many patient populations. Integration of these practices is common in emergency departments but has not been documented in ambulatory oncology clinics, where many patients with cancer present for evaluation of infectious symptoms...
June 1, 2016: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/27181924/transplantations-of-frozen-thawed-ovarian-tissue-demonstrate-high-reproductive-performance-and-the-need-to-revise-restrictive-criteria
#7
Dror Meirow, Hila Ra'anani, Moran Shapira, Masha Brenghausen, Sanaz Derech Chaim, Sarit Aviel-Ronen, Ninette Amariglio, Eyal Schiff, Raoul Orvieto, Jehoshua Dor
OBJECTIVE: To report the single-center results of orthotopic retransplantations of cryopreserved ovarian tissue in cancer survivors and evaluate the validity of commonly accepted procedure limitations. DESIGN: Prospective cohort study. SETTING: Tertiary university-affiliated assisted reproduction technology (ART) and oncology centers. PATIENT(S): Twenty cancer survivors who underwent ovarian transplantation of frozen-thawed ovarian tissue with the aim to conceive...
August 2016: Fertility and Sterility
https://www.readbyqxmd.com/read/27107610/low-bacterial-diet-versus-control-diet-to-prevent-infection-in-cancer-patients-treated-with-chemotherapy-causing-episodes-of-neutropenia
#8
REVIEW
Elvira C van Dalen, Arno Mank, Edith Leclercq, Renée L Mulder, Michelle Davies, Marie José Kersten, Marianne D van de Wetering
BACKGROUND: Neutropenia is a potentially serious side effect of chemotherapy and a major risk factor for infection, which can be life-threatening. It has been hypothesised that a low bacterial diet (LBD) can prevent infection and (infection-related) mortality in cancer patients receiving chemotherapy that causes episodes of neutropenia, but much remains unclear. This review is an update of a previously published Cochrane review. OBJECTIVES: The primary objective of this review was to determine the efficacy of an LBD versus a control diet in preventing infection and in decreasing (infection-related) mortality in adult and paediatric cancer patients receiving chemotherapy that causes episodes of neutropenia...
April 24, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27069074/us-intergroup-trial-of-response-adapted-therapy-for-stage-iii-to-iv-hodgkin-lymphoma-using-early-interim-fluorodeoxyglucose-positron-emission-tomography-imaging-southwest-oncology-group-s0816
#9
Oliver W Press, Hongli Li, Heiko Schöder, David J Straus, Craig H Moskowitz, Michael LeBlanc, Lisa M Rimsza, Nancy L Bartlett, Andrew M Evens, Erik S Mittra, Ann S LaCasce, John W Sweetenham, Paul M Barr, Michelle A Fanale, Michael V Knopp, Ariela Noy, Eric D Hsi, James R Cook, Mary Jo Lechowicz, Randy D Gascoyne, John P Leonard, Brad S Kahl, Bruce D Cheson, Richard I Fisher, Jonathan W Friedberg
PURPOSE: Four US National Clinical Trials Network components (Southwest Oncology Group, Cancer and Leukemia Group B/Alliance, Eastern Cooperative Oncology Group, and the AIDS Malignancy Consortium) conducted a phase II Intergroup clinical trial that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to determine the utility of response-adapted therapy for stage III to IV classic Hodgkin lymphoma. PATIENTS AND METHODS: The Southwest Oncology Group S0816 (Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma) trial enrolled 358 HIV-negative patients between July 1, 2009, and December 2, 2012...
June 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26907641/the-outcome-of-critically-ill-pediatric-cancer-patients-admitted-to-the-pediatric-intensive-care-unit-in-a-tertiary-university-oncology-center-in-a-developing-country-a-5-year-experience
#10
Amany M Ali, Heba A Sayed, Mahmoud M Mohammed
INTRODUCTION: Cancer remains a major cause of death in children, but recent advances in supportive care and progress in the use of chemotherapy have considerably improved the prognosis. The need for intensive care management in pediatric oncology patients is increasing. However, studies demonstrating their outcome in the literature are still deficient, especially in developing countries. Here, we aim to report our experience in managing patients admitted to the pediatric intensive care unit (PICU) at South Egypt Cancer Institute, a tertiary university oncology center in a developing country...
July 2016: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/26780112/varicella-vaccination-in-pediatric-oncology-patients-without-interruption-of-chemotherapy
#11
Marianne D van de Wetering, Mireille T M Vossen, Machiel H Jansen, Hubert N Caron, Taco W Kuijpers
BACKGROUND: Morbidity and mortality from primary varicella-zoster virus (VZV) infection is increased in immunocompromised children. Vaccination of VZV-seronegative cancer patients with live-attenuated varicella vaccine is safe when chemotherapy is interrupted. However, VZV vaccination without interruption of chemotherapy would be preferable. OBJECTIVE: To vaccinate VZV-seronegative pediatric oncology patients with live-attenuated VZV vaccine without interrupting their chemotherapy...
February 2016: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/26486208/predictive-factors-of-febrile-neutropenia-induced-by-anticancer-chemotherapy-in-the-south-of-tunisia
#12
Afef Khanfir, Wala Ben Kridis, Safia Masmoudi, Senda Mezghani, Adnen Hammami, Mounir Frikha
INTRODUCTION: Febrile Neutropenia (FN) secondary to chemotherapy is the most common and the earliest hematological complication. The aim of this work is to study the predictive factors of FN. Materiel and Methods: This is a retrospective study including 186 episodes of FN induced by chemotherapy treated in the department of oncology at Sfax in southern Tunisia during the period between 1 January 2006 and 31 December 2010. RESULT: The mean age of patients was 40 years...
2016: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/26417037/attitudes-and-beliefs-toward-supportive-and-palliative-care-referral-among-hematologic-and-solid-tumor-oncology-specialists
#13
David Hui, Minjeong Park, Diane Liu, Akhila Reddy, Shalini Dalal, Eduardo Bruera
BACKGROUND: Palliative care (PC) referrals are often delayed for patients with hematologic malignancies. We examined the differences in attitudes and beliefs toward PC referral between hematologic and solid tumor specialists and how their perception changed with use of the service name "supportive care" (SC). MATERIALS AND METHODS: We randomly surveyed 120 hematologic and 120 solid tumor oncology specialists at our tertiary care cancer center to examine their attitudes and beliefs toward PC and SC referral...
November 2015: Oncologist
https://www.readbyqxmd.com/read/26407409/infections-caused-by-rapidly-growing-mycobacteria-spp-in-children-and-adolescents-with-cancer
#14
Nopporn Apiwattankul, Patricia M Flynn, Randall T Hayden, Elisabeth E Adderson
BACKGROUND: Rapidly growing mycobacteria (RGM) infections in pediatric oncology patients have not been completely characterized. METHODS: We reviewed medical records of oncology patients at St. Jude Children's Research Hospital (St. Jude) from 1990 to 2010 with RGM infections and summarized the results of previously published cases. RESULTS: Twenty-five St. Jude patients had 27 episodes of infection. Approximately half of the cases occurred in patients with hematological malignancies and in males; infections were more common in white patients...
June 2015: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/26257093/anaplastic-large-cell-lymphoma-in-central-america-a-report-from-the-central-american-association-of-pediatric-hematology-oncology-ahopca
#15
Francesco Ceppi, Roberta Ortiz, Federico Antillón, Roberto Vasquez, Wendy Gomez, Jessica Gamboa, Claudia Garrido, Guillermo Chantada, Armando Peña, Sumit Gupta
BACKGROUND: Although anaplastic large cell lymphoma (ALCL) is curable in high-income countries (HIC), data from low- and middle-income countries (LMIC) are lacking. We therefore conducted a retrospective study of the Central American Association of Pediatric Hematology Oncology (AHOPCA) experience in treating ALCL. PROCEDURE: We included all patients age <18 years newly diagnosed with ALCL treated between 2000 and 2013 in seven AHOPCA institutions. Retrospective data were extracted from the Pediatric Oncology Network Database...
January 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/26154543/assessment-of-adherence-to-the-guidelines-for-the-management-of-nausea-and-vomiting-induced-by-chemotherapy
#16
Monique Sedlmaier França, Pedro Luiz Serrano Usón Junior, Yuri Philippe Pimentel Vieira Antunes, Bernard Lobato Prado, Carlos del Cistia Donnarumma, Taciana Sousa Mutão, Heloisa Veasey Rodrigues, Auro del Giglio
OBJECTIVE: To assess adherence of the prescribing physicians in a private cancer care center to the American Society of Clinical Oncology guideline for antiemetic prophylaxis, in the first cycle of antineoplastic chemotherapy. METHODS: A total of 139 chemotherapy regimens, of 105 patients, were evaluated retrospectively from 2011 to 2013. RESULTS: We observed 78% of non-adherence to the guideline rate. The main disagreements with the directive were the prescription of higher doses of dexamethasone and excessive use of 5-HT3 antagonist for low risk emetogenic chemotherapy regimens...
April 2015: Einstein
https://www.readbyqxmd.com/read/26067861/evaluation-of-the-hematologic-safety-of-same-day-versus-standard-administration-24-to-72-hour-delay-of-pegfilgrastim-in-gynecology-oncology-patients-undergoing-cytotoxic-chemotherapy
#17
COMPARATIVE STUDY
Caroline C Billingsley, Samuel N Jacobson, Sarah M Crafton, Aleia K Crim, Quan Li, Erinn M Hade, David E Cohn, Jeffrey M Fowler, Larry J Copeland, Ritu Salani, Floor J Backes, David M O'Malley
OBJECTIVE: We assessed the safety and efficacy of administration of pegfilgrastim on the same day compared with standard administration 24 to 72 hours after chemotherapy in patients with gynecologic malignancies. METHODS: A retrospective review was conducted on patients undergoing pegfilgrastim to mitigate the myelosuppressive consequences of chemotherapy. The primary outcome was incidence of grade 3 to 4 neutropenia following pegfilgrastim for same-day administration (D1) versus standard administration (D2+)...
September 2015: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/26057184/infection-with-multidrug-resistant-gram-negative-bacteria-in-a-pediatric-oncology-intensive-care-unit-risk-factors-and-outcomes
#18
Patrícia de Oliveira Costa, Elias Hallack Atta, André Ricardo Araújo da Silva
OBJECTIVE: This study aimed at evaluating the predictors and outcomes associated with multidrug-resistant gram-negative bacterial (MDR-GNB) infections in an oncology pediatric intensive care unit (PICU). METHODS: Data were collected relating to all episodes of GNB infection that occurred in a PICU between January of 2009 and December of 2012. GNB infections were divided into two groups for comparison: (1) infections attributed to MDR-GNB and (2) infections attributed to non-MDR-GNB...
September 2015: Jornal de Pediatria
https://www.readbyqxmd.com/read/26000590/ibrutinib-a-new-targeted-therapy-for-hematologic-cancers
#19
Caroline R Smithson, Susan M Schneider
BACKGROUND: Hematologic cancers can occur from the overactivity of Bruton's tyrosine kinase, a proto-oncogene in blood cell maturation. Ibrutinib, a new oral targeted therapy drug, is the first agent that binds to the Bruton's tyrosine kinases and inhibits overgrowth of B cells. In blocking this overgrowth, ibrutinib has been shown to achieve lengthy remissions for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Remissions are highly valued in these cancers; cure is rare in MCL, and CLL is incurable...
June 2015: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/25976292/a-phase-1-dosing-study-of-ruxolitinib-in-children-with-relapsed-or-refractory-solid-tumors-leukemias-or-myeloproliferative-neoplasms-a-children-s-oncology-group-phase-1-consortium-study-advl1011
#20
Mignon L Loh, Sarah K Tasian, Karen R Rabin, Patrick Brown, Daniel Magoon, Joel M Reid, Xuejun Chen, Charlotte H Ahern, Brenda J Weigel, Susan M Blaney
BACKGROUND: Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations. PROCEDURE: A phase 1 trial of ruxolitinib was performed to determine the maximum tolerated or recommended phase 2 dose, dose-limiting toxicities (DLTs), pharmacokinetics (PK), and pharmacodynamics (PD) in children with recurrent/refractory solid tumors (STs). Ruxolitinib was administered twice daily (BID) in 28-day cycles at five dose levels (15, 21, 29, 39, and 50 mg/m(2)/dose)...
October 2015: Pediatric Blood & Cancer
keyword
keyword
16392
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"